Pulmonary Pharmacology and Therapeutics This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Adrenomedullin mediates pro-angiogenic and pro-inflammatory cytokines in asthma and COPD
ConclusionsThese data suggest that AM mediates the secretion of pro-angiogenic and pro-inflammatory cytokines in a cell-type and/or a disease-specific way, explaining its association with clinical outcomes in COPD. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - January 25, 2019 Category: Respiratory Medicine Source Type: research

Limitations of the results from randomized clinical trials involving intravenous and nebulised magnesium sulphate in adults with severe acute asthma
Publication date: Available online 17 January 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Eugen Javor, Sanja Popović GrleAbstractThe role of intravenous (IV) or nebulised magnesium sulphate (MgSO4) in the treatment of severe acute asthma in adults is unclear. A controversy exists regarding its efficacy. In children MgSO4 has a more evident clinical effect, but the child population has not been considered in this work. The applicability of the results from randomized clinical trials (RCTs) involving MgSO4 in adult population is questioned in the optimal treatment of asthma exacerbations. According to the ne...
Source: Pulmonary Pharmacology and Therapeutics - January 18, 2019 Category: Respiratory Medicine Source Type: research

Vitamin D prevents experimental lung fibrosis and predicts survival in patients with idiopathic pulmonary fibrosis
ConclusionsVitD could serve as a prognosticator and potential therapeutic target in patients with IPF. Further studies are sorely needed. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - January 17, 2019 Category: Respiratory Medicine Source Type: research

Editorial Board
Publication date: February 2019Source: Pulmonary Pharmacology & Therapeutics, Volume 54Author(s): (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - January 16, 2019 Category: Respiratory Medicine Source Type: research

Alteplase and DNase for the treatment of pleural empyema in rats
ConclusionsAlteplase, DNase and alteplase + DNase changed significantly physical and chemical properties of experimental empyema at fibrinopurulent phase: alteplase reduced molecular size larger than 135 nm and DNase reduced viscosity. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - January 16, 2019 Category: Respiratory Medicine Source Type: research

The anti-proliferative effects of adiponectin on human lung adenocarcinoma A549 cells and oxidative stress involvement
Publication date: Available online 15 January 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): E. Nigro, P. Stiuso, M.G. Matera, M.L. Monaco, M. Caraglia, M. Maniscalco, F. Perrotta, G. Mazzarella, A. Daniele, A. BiancoAbstractAdiponectin (Acrp30) plays an important role in energy metabolism and inflammation. Recently, in vivo serum Acrp30 levels have been reported to be correlated to risk of developing several types of cancers such as lung cancer, and in vitro studies have demonstrated a role for Acrp30 in the control of cell proliferation and survival. However, the molecular effects of Acrp30 on lung cancer ha...
Source: Pulmonary Pharmacology and Therapeutics - January 16, 2019 Category: Respiratory Medicine Source Type: research

Penehyclidine effects the angiogenic potential of pulmonary microvascular endothelial cells
Publication date: Available online 11 January 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Peilin Xie, Zhen Zheng, Lihua Jiang, Songwei WuAbstractThe present study sought to determine the pharmacological effects of penehyclidine, an anticholinergic agent, on the angiogenic capacity of pulmonary microvascular endothelial cells (PMVECs). In vitro Matrigel network formation assay, cell proliferation assay, cell-matrix adhesion assay, and wound-healing assay were performed in PMVECs with or without exposure to penehyclidine or, in some cases, glycopyrrolate or acetylcholine, over a concentration range. In additi...
Source: Pulmonary Pharmacology and Therapeutics - January 12, 2019 Category: Respiratory Medicine Source Type: research

GYY4137 attenuates LPS-induced acute lung injury via heme oxygenase-1 modulation
This study investigated the role of GYY4137 in acute lung injury (ALI) via HO-1 regulation. Lung injury was assessed in mice challenged with intratracheal lipopolysaccharide (LPS) and the mechanism of anti-inflammatory effects of GYY4137 was investigated in mice and RAW264.7 cells. GYY4137 reduced the LPS-mediated pulmonary injury and neutrophil infiltration, and inhibited the LPS-induced production of proinflammatory cytokines, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) expression. Moreover, GYY4137 suppressed the LPS-evoked NF-κB activation in RAW264.7 cells. GYY4137, not time-expired GYY413...
Source: Pulmonary Pharmacology and Therapeutics - January 1, 2019 Category: Respiratory Medicine Source Type: research

Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life
We describe herein the drop-out rate observed with mepolizumab in real life, because this datum can indirectly reflect the safety and tolerability aspects. The demographic and clinical data of patients receiving mepolizumab for severe asthma were collected, and the number and reasons for discontinuation of the treatment were analyzed. The database involves 143 patients (67 male, age range 19–80 year) who received at least one dose of mepolizumab. The observed discontinuation rate was 6/143 (4.2%). Five out of 6 discontinuations were due to lack of response, and one was an adverse event (urticaria) probably related to the...
Source: Pulmonary Pharmacology and Therapeutics - December 29, 2018 Category: Respiratory Medicine Source Type: research

Efficacy and safety of a novel nitric oxide generator for the treatment of neonatal pulmonary hypertension: Experimental and clinical studies
Publication date: Available online 8 December 2018Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Fernanda Blasina, Lucía Vaamonde, Fernando Silvera, Gonzalo Solla, Juan Andrés Abin-Carriquiry, Carmen Gutiérrez, Pilar Beltramo, Irene García, Miguel MartellAbstractPersistent pulmonary hypertension of the newborn (PPHN) is a complex pathology resulting from a failure of the post-natal reduction in pulmonary vascular resistance leading to hypoxemia. The standard therapy is inhaled Nitric Oxide (NO) improving oxygenation but its availability is limited, especially in hospitals with restricted financial resources. W...
Source: Pulmonary Pharmacology and Therapeutics - December 8, 2018 Category: Respiratory Medicine Source Type: research

Arbutin attenuates LPS-induced lung injury via Sirt1/ Nrf2/ NF-κBp65 pathway
Publication date: Available online 6 December 2018Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Jinyan Ye, Minqiang Guan, Yao Lu, Dan Zhang, Chengye Li, Caicun ZhouAbstractThe main goal of this study was to evaluate the effects of arbutin (AR) on lipopolysaccharide (LPS)-induced lung injury. A lung injury rat model was established by intravenous LPS administration. We found that levels of inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6) in both serum and lung tissue were significant increased after LPS challenge. In addition, pathologica...
Source: Pulmonary Pharmacology and Therapeutics - December 6, 2018 Category: Respiratory Medicine Source Type: research

The effect of erdosteine on airway defence mechanisms and inflammatory cytokines in the settings of allergic inflammation
ConclusionIn summary, we can state, that erdosteine is multi-action drug and it seems to have many beneficial and complementary effect in the management of chronic inflammatory airway diseases complicated by viscous mucus. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 28, 2018 Category: Respiratory Medicine Source Type: research

Effect of mesenchymal stromal (stem) cell (MSC) transplantation in asthmatic animal models: A systematic review and meta-analysis
ConclusionFindings of the current systemic review suggested a potential role for MSCs in asthma treatment although it is still challenging in clinical practice. The mechanisms of MSCs in pre-clinical asthma treatment may be associated with attenuating airway inflammation through regulating Th1 and Th2 cytokines. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 27, 2018 Category: Respiratory Medicine Source Type: research

Attenuation of pulmonary fibrosis in type I collagen-targeted reporter mice with ALK-5 inhibitors
Publication date: Available online 15 November 2018Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Hideki Terashima, Misato Aonuma, Hiroshi Tsuchida, Kotaro Sugimoto, Mika Yokoyama, Mikio KatoAbstractIdiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease, and consequently, effective antifibrotic drugs are strongly desired. Although we have previously reported a validated Col1a1-Luc Tg rat model for fibrosis, there are only a few mouse models that enable the evaluation of fibrosis in a short time period and with high sensitivity. Therefore, we generated a Col1a1-internal ribosome entry site (IRES)-Lu...
Source: Pulmonary Pharmacology and Therapeutics - November 16, 2018 Category: Respiratory Medicine Source Type: research

Editorial Board
Publication date: December 2018Source: Pulmonary Pharmacology & Therapeutics, Volume 53Author(s): (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 16, 2018 Category: Respiratory Medicine Source Type: research